# Pegylated Recombinant Human Arginase 1 in Combination With Oxaliplatin and Capecitabine for the Treatment of HCC

> **NCT02089633** · PHASE2 · COMPLETED · sponsor: **Bio-Cancer Treatment International Limited** · enrollment: 17 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **BIOLOGICAL:** PACOX

## Key facts

- **NCT ID:** NCT02089633
- **Lead sponsor:** Bio-Cancer Treatment International Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2016-09
- **Final completion:** 2016-10
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2017-07-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02089633

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02089633, "Pegylated Recombinant Human Arginase 1 in Combination With Oxaliplatin and Capecitabine for the Treatment of HCC". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02089633. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*